Actively Recruiting
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Led by Kura Oncology, Inc. · Updated on 2026-04-14
300
Participants Needed
40
Research Sites
180 weeks
Total Duration
On this page
Sponsors
K
Kura Oncology, Inc.
Lead Sponsor
M
Mirati Therapeutics Inc.
Collaborating Sponsor
AI-Summary
What this Trial Is About
This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess KO-2806, a farnesyltransferase inhibitor (FTI), as a monotherapy and in combination, in adult patients with advanced solid tumors.
CONDITIONS
Official Title
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- At least 18 years of age
- Histologically or cytologically confirmed advanced solid tumors
- For KO-2806 monotherapy: progressed on or refractory to standard treatments with HRAS-mutant/amplified tumors, HRAS-overexpressing HNSCC, KRAS/NRAS/HRAS-mutant or amplified NSCLC or CRC, or KRAS-mutant/amplified PDAC
- For combination arms: received prior systemic therapy with immune-oncology treatment for RCC or KRAS G12C-mutant NSCLC, CRC, or PDAC as specified
- Cabozantinib-na�efve patients with specific prior therapy criteria for certain arms
- Measurable disease by RECIST v1.1 criteria
- Karnofsky Performance Status of 70 or higher with no significant deterioration in the last 2 weeks
- Acceptable liver, kidney, endocrine, and blood function
- Other protocol-defined inclusion criteria may apply
You will not qualify if you...
- Use of anticancer therapy within 14 days or 5 half-lives (whichever is shorter) before Cycle 1 Day 1
- Prior treatment with any farnesyltransferase inhibitor or HRAS inhibitor
- Major surgery within 28 days before Cycle 1 Day 1 without full recovery
- Spinal cord compression, leptomeningeal disease, or active CNS metastases
- Unresolved toxicity from prior therapy (except hair loss)
- Active or prior autoimmune or inflammatory disorders within 5 years (with exceptions)
- Active, uncontrolled infections needing systemic therapy
- Inability to swallow or gastrointestinal conditions affecting drug absorption
- Inadequate cardiac or vascular function including recent unstable angina, heart attack, stroke, prolonged QTcF, or severe heart failure
- Other invasive malignancy within 2 years
- Other protocol-defined exclusion criteria may apply
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 40 locations
1
Mayo Clinic Comprehensive Cancer Center
Phoenix, Arizona, United States, 85054
Actively Recruiting
2
University of Arizona
Tucson, Arizona, United States, 85721
Actively Recruiting
3
University of Arizona
Tucson, Arizona, United States, 85724
Actively Recruiting
4
University of Southern California
Los Angeles, California, United States, 90033
Actively Recruiting
5
Cedars-Sinai Medical Center
Los Angeles, California, United States, 90048
Actively Recruiting
6
UCLA Department of Medicine
Los Angeles, California, United States, 90095
Actively Recruiting
7
Sarah Cannon Research Institute at HealthONE
Denver, Colorado, United States, 80218
Actively Recruiting
8
AdventHealth Celebration
Celebration, Florida, United States, 34747
Actively Recruiting
9
Mayo Clinic Comprehensive Cancer Center
Jacksonville, Florida, United States, 32224
Actively Recruiting
10
Florida Cancer Specialists
Sarasota, Florida, United States, 34232
Actively Recruiting
11
University of Iowa Hospitals & Clinics
Iowa City, Iowa, United States, 52242
Actively Recruiting
12
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02215
Actively Recruiting
13
Henry Ford Health System
Detroit, Michigan, United States, 48202
Actively Recruiting
14
Mayo Clinic Comprehensive Cancer Center
Rochester, Minnesota, United States, 55905
Actively Recruiting
15
Washington University School of Medicine
St Louis, Missouri, United States, 63110
Actively Recruiting
16
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, United States, 08901
Actively Recruiting
17
Ohio State University
Columbus, Ohio, United States, 43210
Actively Recruiting
18
OU Stephenson Cancer Center
Oklahoma City, Oklahoma, United States, 73104
Actively Recruiting
19
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, United States, 15232
Actively Recruiting
20
SCRI - Oncology Partners
Nashville, Tennessee, United States, 37203
Actively Recruiting
21
UT Southwestern Simmons Cancer Center
Dallas, Texas, United States, 75235
Actively Recruiting
22
MD Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
23
University of Wisconsin (Carbone Cancer Center)
Madison, Wisconsin, United States, 53792
Actively Recruiting
24
Centre Leon Berard
Lyon, France, 69495
Actively Recruiting
25
Oncologie médicale - Pitié-Salpêtrière
Paris, France, 75013
Actively Recruiting
26
Hopital Européen Georges Pompidou
Paris, France, 75015
Actively Recruiting
27
Institut Universitaire du Cancer Toulouse - Oncopole
Toulouse, France, 31059
Actively Recruiting
28
Charité - Universitätsmedizin Berlin
Berlin, Germany, 10117
Actively Recruiting
29
Charité - Universitätsmedizin Berlin
Berlin, Germany, 12203
Actively Recruiting
30
Universitätsklinikum Ulm
Ulm, Germany, 89081
Actively Recruiting
31
Universitätsklinikum Würzburg
Würzburg, Germany, 97080
Actively Recruiting
32
Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi IRCCS
Bologna, Italy, 40138
Actively Recruiting
33
Fondazione Piemonte per l'Oncologia - IRCCs Candiolo
Candiolo, Italy, 10060
Actively Recruiting
34
Istituto Nazionale Tumori IRCCS
Naples, Italy, 80131
Actively Recruiting
35
Humanitas University
Rozzano, Italy, 20089
Actively Recruiting
36
AOU Verona - Centro Ricerche Cliniche di Verona
Verona, Italy, 37134
Actively Recruiting
37
Hospital Universitari Vall d'Hebron
Barcelona, Spain, 08035
Actively Recruiting
38
Hospital de la Santa Creu i de Sant Pau
Barcelona, Spain, 08041
Actively Recruiting
39
Hospital HM Sanchinarro START Madrid-CIOCC
Madrid, Spain, 28050
Actively Recruiting
40
Hospital Universitario Virgen del Rocío
Seville, Spain, 41013
Actively Recruiting
Research Team
K
Kura Medical Information
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
7
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here